Novel therapeutic antibody

NOVA-CARE aims to establish preclinical efficacy in mouse and porcine disease models for a novel therapeutic monoclonal antibody (mAb) to prevent non-ischaemic heart failure (NI-HF) by targeting EDA-fibronectin (EDA).

This protein is upregulated during adverse cardiac remodelling, which leads to heart failure (HF). In addition, a companion diagnostic will be developed using biomarkers linked to EDA expression, to identify patients at risk for developing NI-HF, and to optimize mAb treatment.

The NOVA-CARE project was awarded a Eurostars grant, based on a proposal written by Catalyze.